Aprepitant and Vincristine interaction
Aprepitant and Vincristine: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.
Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.
What the FDA labels say
From the Vincristine (VinCRIStine Sulfate) label · effective 2026-02-17
Therefore, the concomitant use of strong CYP3A inhibitors with vincristine sulfate should be avoided.
Patients should be frequently monitored for adverse reactions with concomitant use of moderate CYP3A inhibitors (e.g., fluconazole) with vincristine sulfate.
Concurrent use of strong CYP3A inducers (e.g., St.
From the Aprepitant (CINVANTI) label · effective 2026-04-01
Intervention Vinblastine, vincristine, or ifosfamide or other chemotherapeutic agents Monitor for chemotherapeutic-related adverse reactions.
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.